Cortes JE - Search Results

1

Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia.

Giles FJ, Cortes JE, Thomas DA, Garcia-Manero G, Faderl S, Jeha S, De Jager RL, Kantarjian HM. Giles FJ, et al. Among authors: cortes je. Clin Cancer Res. 2002 Jul;8(7):2134-41. Clin Cancer Res. 2002. PMID: 12114413 Clinical Trial.

2

Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia.

Giles FJ, Garcia-Manero G, Cortes JE, Baker SD, Miller CB, O'Brien SM, Thomas DA, Andreeff M, Bivins C, Jolivet J, Kantarjian HM. Giles FJ, et al. Among authors: cortes je. J Clin Oncol. 2002 Feb 1;20(3):656-64. doi: 10.1200/JCO.2002.20.3.656. J Clin Oncol. 2002. PMID: 11821445 Clinical Trial.

3

Central nervous system relapse in adults with acute lymphoblastic leukemia.

Surapaneni UR, Cortes JE, Thomas D, O'Brien S, Giles FJ, Koller C, Faderl S, Kantarjian H. Surapaneni UR, et al. Among authors: cortes je. Cancer. 2002 Feb 1;94(3):773-9. doi: 10.1002/cncr.10265. Cancer. 2002. PMID: 11857312 Free article.

4

Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia.

Verstovsek S, Kantarjian H, Manshouri T, Cortes J, Giles FJ, Rogers A, Albitar M. Verstovsek S, et al. Blood. 2002 Mar 15;99(6):2265-7. doi: 10.1182/blood.v99.6.2265. Blood. 2002. PMID: 11877311 Free article.

5

Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia.

Cortes J, Thomas D, Rios A, Koller C, O'Brien S, Jeha S, Faderl S, Kantarjian H. Cortes J, et al. Cancer. 2002 Mar 1;94(5):1492-9. doi: 10.1002/cncr.10365. Cancer. 2002. PMID: 11920506 Free article. Clinical Trial.

6

Prognostic significance of Tie-1 protein expression in patients with early chronic phase chronic myeloid leukemia.

Verstovsek S, Kantarjian H, Manshouri T, O'Brien S, Faderl S, Talpaz M, Cortes J, Albitar M. Verstovsek S, et al. Cancer. 2002 Mar 1;94(5):1517-21. doi: 10.1002/cncr.10363. Cancer. 2002. PMID: 11920509 Free article.

7

Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.

O'Brien S, Talpaz M, Cortes J, Shan J, Giles FJ, Faderl S, Thomas D, Garcia-Manero G, Mallard S, Beth M, Koller C, Kornblau S, Andreeff M, Murgo A, Keating M, Kantarjian HM. O'Brien S, et al. Cancer. 2002 Apr 1;94(7):2024-32. doi: 10.1002/cncr.10436. Cancer. 2002. PMID: 11932905 Free article.

8

Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.

Kantarjian HM, Cortes J, O'Brien S, Giles FJ, Albitar M, Rios MB, Shan J, Faderl S, Garcia-Manero G, Thomas DA, Resta D, Talpaz M. Kantarjian HM, et al. Blood. 2002 May 15;99(10):3547-53. doi: 10.1182/blood.v99.10.3547. Blood. 2002. PMID: 11986206 Free article. Clinical Trial.

9

Chemotherapy-induced palmar-plantar erythrodysesthesia syndrome--recall following different chemotherapy agents.

Hui YF, Giles FJ, Cortes JE. Hui YF, et al. Among authors: cortes je. Invest New Drugs. 2002 Feb;20(1):49-53. doi: 10.1023/a:1014421912799. Invest New Drugs. 2002. PMID: 12003194

10

CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia.

Ravandi F, Cortes J, Estrov Z, Thomas D, Giles FJ, Huh YO, Pierce S, O'Brien S, Faderl S, Kantarjian HM. Ravandi F, et al. Leuk Res. 2002 Jul;26(7):643-9. doi: 10.1016/s0145-2126(01)00188-6. Leuk Res. 2002. PMID: 12008081

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,104 results

Search Page

Filters